Glenmark Receives 6 USFDA Observations for Goa Manufacturing Plant
Glenmark
New Delhi: Glenmark Pharmaceuticals Limited has informed the stock exchanges that the United States Food and Drug Administration (USFDA) has completed a Good Manufacturing Practice (GMP) inspection at the company's Goa manufacturing facility, issuing a Form 483 with six observations at the conclusion of the inspection.
The U.S. FDA conducted the GMP inspection at Glenmark's manufacturing facility in Goa, India, from June 22, 2026, to June 30, 2026. The company stated that at the conclusion of the inspection, the U.S. FDA issued a Form 483 containing six observations.
Glenmark clarified that none of the observations were related to data integrity, adding that all six observations are procedural in nature and none are repeat observations.
Glenmark further informed that it does not anticipate any impact on the supply of its commercial products as a result of the inspection outcome.The company stated that it will work in close collaboration with the U.S. FDA to address all the observations and will submit its response to the regulator within the stipulated timeline. Glenmark also informed investors that it will keep the stock exchanges updated if there are any further developments regarding the inspection.
According to the Glenmark Pharmaceuticals regulatory filing, the U.S. FDA inspection of the Goa manufacturing facility concluded with six procedural observations in the Form 483. The company emphasized that no data integrity observations were reported, none of the observations are repeat observations, and the inspection outcome is not expected to affect the supply of its commercial products. Glenmark added that it will respond to the observations within the timeline prescribed by the U.S. FDA.
